Scholars Central

Review articlePublished 20 Nov 2017

Contemporary Profile of Chronic Dialysis Patients Receiving Oral P2Y12 Inhibitors: A Single Center Experience

Authors: Rafia S. Rasu, Busuyi Olotu, Margaret L Hansen, Deepa Raghavan, Milind A. Phadnis, Jonathan D Mahnken, Nishank Jain

Journal of Renal Medicine

Volume 1 · Issue 3 · Pages 14

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Oral P2Y12 inhibitors including clopidogrel, prasugrel, and ticagrelor are FDA-approved for patients presenting with acute coronary syndrome. Due to systematic exclusion of patients with end stage renal disease (ESRD) on outpatient dialysis from major trials, scarce data exist to report contemporary use of these drugs in ESRD patients. Study design: Retrospective chart review of patient records. Setting and participants: From 2011-2015, 848 ESRD patients (32%) had prescriptions for oral P2Y12 inhibitors such as clopidogrel, prasugrel, and ticagrelor. Differences in patient characteristics as well as major adverse events (MAEs) defined as a composite of new coronary stent placement, heart valve replacement, coronary artery bypass graft or amputation; and all-cause death, nose and gastrointestinal (GI) bleeding were collected. Results: Of the 85 patient records that were reviewed, there were 68.2% males, 66.7% whites, 21.4% African Americans and 9% on peritoneal dialysis. There were no differences in baseline characteristics of patients who were prescribed the three drugs. 18 (21.2%) deaths, 57 (67.1%) MAEs, 9 (10.6%) nose bleeds and 13 (15.3%) GI bleeds were identified over 16.5 months follow up. There was no difference in clinical outcome variables between the three groups. Conclusion: Oral P2Y12 inhibitors were commonly prescribed to ESRD patients despite the inadequacy of data and there were no differences in the profiles of ESRD patients who were prescribed the three drugs or their outcome variables. All-cause death, MAEs, nose and GI bleeds were common in these patients. Future studies are needed to investigate clinical benefits and risks associated with use of P2Y12 inhibitors in this high-risk patient population.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Renal Medicine
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Rafia S. Rasu”
  • BylineArticles whose byline prints “Busuyi Olotu”
  • BylineArticles whose byline prints “Margaret L Hansen”
  • BylineArticles whose byline prints “Deepa Raghavan”
  • BylineArticles whose byline prints “Milind A. Phadnis”
  • BylineArticles whose byline prints “Jonathan D Mahnken”
  • BylineArticles whose byline prints “Nishank Jain”